生物活性

• 描述Photodynamic therapy (PDT) has been accepted as an alternative clinical cancer treatment modality. Similar to chemotherapy, PDT requires agents (photosensitizers) which exhibit selectivity for tumors and in common with radiotherapy, the mode of action involves the use of electromagnetic radiation in order to generate reactive oxygen species (ROS). Cyclic Arg-Gly-Asp (cRGD) peptide represents a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis. Photochlor, a chlorophyll-based photosensitizer, is conjugated to cRGD and the related analogues. In α(v)β(3) integrin overexpressing U87 and 4T1 cell lines, compared to photochlor, the photochlor-cRGD conjugate in which the arginine and aspartic acid moieties were available for binding to two subunits of α(v)β(3) integrin showed faster clearance, enhanced tumor imaging and enhanced PDT efficacy at 2-4 h postinjection^[1]. A combination treatment regimen was devised in which Colo26-HA tumor-bearing BALB/c mice were treated with a photochlor-PDT regimen known to lead to enhanced anti-tumor immunity (0.4 μmoles/kg photochlor followed 18 h later by illumination with 665 nm light for a total dose of 48 J/cm²)^[2].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00470496	Recurrent Adenoid Cystic Carci... more >>noma of the Oral Cavity Recurrent Basal Cell Carcinoma of the Lip Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Recurrent Lymphoepithelioma of the Nasopharynx Recurrent Lymphoepithelioma of the Oropharynx Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Recurrent Mucoepidermoid Carcinoma of the Oral Cavity Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Thyroid Cancer Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Stage I Adenoid Cystic Carcinoma of the Oral Cavity Stage I Basal Cell Carcinoma of the Lip Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Stage I Follicular Thyroid Cancer Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Stage I Lymphoepithelioma of the Nasopharynx Stage I Lymphoepithelioma of the Oropharynx Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Stage I Mucoepidermoid Carcinoma of the Oral Cavity Stage I Papillary Thyroid Cancer Stage I Salivary Gland Cancer Stage I Squamous Cell Carcinoma of the Hypopharynx Stage I Squamous Cell Carcinoma of the Larynx Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity Stage I Squamous Cell Carcinoma of the Oropharynx Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage I Verrucous Carcinoma of the Larynx Stage I Verrucous Carcinoma of the Oral Cavity Stage II Adenoid Cystic Carcinoma of the Oral Cavity Stage II Basal Cell Carcinoma of the Lip Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Stage II Follicular Thyroid Cancer Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Stage II Lymphoepithelioma of the Nasopharynx Stage II Lymphoepithelioma of the Oropharynx Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Stage II Mucoepidermoid Carcinoma of the Oral Cavity Stage II Papillary Thyroid Cancer Stage II Salivary Gland Cancer Stage II Squamous Cell Carcinoma of the Hypopharynx Stage II Squamous Cell Carcinoma of the Larynx Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity Stage II Squamous Cell Carcinoma of the Oropharynx Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage II Verrucous Carcinoma of the Larynx Stage II Verrucous Carcinoma of the Oral Cavity Collapse <<	Phase 1	Completed	-	United States, New York ... more >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Collapse <<
  NCT01668823	Adenocarcinoma of the Lung ... more >> Large Cell Lung Cancer Recurrent Non-small Cell Lung Cancer Squamous Cell Lung Cancer Stage 0 Non-small Cell Lung Cancer Collapse <<	Phase 1	Completed	-	United States, New York ... more >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Collapse <<
  NCT03090412	Stage I Oral Cavity Squamous C... more >>ell Carcinoma Stage II Oral Cavity Squamous Cell Carcinoma Collapse <<	Phase 2	Recruiting	November 2, 2021	United States, New York ... more >> Roswell Park Cancer Institute Recruiting Buffalo, New York, United States, 14263 Contact: Roswell Park    877-275-7724    AskRPCI@RoswellPark.org    Principal Investigator: Hassan Arshad          University of Rocherster Recruiting Rochester, New York, United States, 14642 Contact: Paul Allen    585-275-1186    Paul_Allen@URMC.Rochester.edu Collapse <<

• 更多
• 参考文献

• [1] Srivatsan A, Ethirajan M, Pandey SK, et al. Conjugation of cRGD peptide to chlorophyll a based photosensitizer (HPPH) alters its pharmacokinetics with enhanced tumor-imaging and photosensitizing (PDT) efficacy. Mol Pharm. 2011;8(4):1186‐1197

  [2] Shams M, Owczarczak B, Manderscheid-Kern P, Bellnier DA, Gollnick SO. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol Immunother. 2015;64(3):287‐297